A federal judge in New Jersey recently granted summary judgment to Plavix drug makers Bristol Myers-Squibb Company (“BMS”), Sanofi-Aventis U.S., L.L.C., Sanofi-Aventis U.S., Inc., and Sanofi-Synthelabo, Inc. in a lawsuit alleging that plaintiff’s gastrointestinal bleeding was caused by defendants’ prescription drug Plavix.

Plaintiff alleged that she suffered injuries as a result of defendants’ design, development, manufacture, promoting, marketing, distributing, labeling, and sale of Plavix, an anti-clotting medication.

Plavix was initially approved by the FDA for individuals with recent heart attack, stroke (including Transient Ischemic Attack or “TIA”), or peripheral arterial disease. Plavix inhibits blood platelets from forming clots and therefore increases the risk of bleeding. Its labeling has included information about that risk.

Plaintiff’s complaint asserts product liability related causes of action under California state law, for defective design, manufacturing defect, failure to warn, and negligence.

Continue Reading Plavix Decision Raises Questions About Learned Intermediary Doctrine

New Jersey was once one of the premiere venues for Mass Tort filings (now termed Multicounty Litigations in New Jersey). One of the reasons for this was the obvious fact that many large pharmaceutical companies maintain their principal place of business in New Jersey, making it very difficult for those pharmaceutical companies to remove cases brought against them in New Jersey Superior Court to federal District Court, due to the “forum defendant” rule (28 U.S.C. § 1441(b)(2)). Perhaps a more significant reason was the makeup of the New Jersey Superior Court’s Mass Tort bench at a time when nationally recognized jurists, such as the late Judge Carol E. Higbee, were on the cutting edge of high-stakes pharmaceutical litigation, like the seminal Vioxx cases.

Continue Reading SCOTUS Decision in Plavix Litigation Could Lead to a Resurgence in New Jersey Mass Tort Filings

As we have previously reported, the makers of Plavix®, Sanofi-Aventis and Bristol-Myers Squibb, have been fined for engaging in anti-competitive behavior related to the sale and marketing of the medication. Plavix® is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix® have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

Plavix® is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets. The drug works to prevent blood clots.

Hawaii Attorney General David Louie recently filed a lawsuit against Bristol-Myers Squibb and Sanofi-Aventis alleging unfair and deceptive marketing of the blood-thinning drug to Hawaii consumers. The suit alleges that the manufacturers of Plavix®, began deceptively and unfairly labeling and marketing the drug in 1998 by failing to disclose that Plavix® has a diminished or no effect on approximately 30 percent of the population because they metabolize the drug poorly, due to their genetic traits or because they take other drugs that affect the body’s ability to metabolize Plavix®. The drug does not prevent heart attacks, strokes, or vascular death in such patients but instead puts them at considerable risk for gastrointestinal bleeding and other complications.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

As we have previously reported, Plavix®, manufactured by Sanofi-Aventis and Bristol-Myers Squibb (collectively, “Defendants”), is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix® have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

Plavix® is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets.  The drug works to prevent blood clots.

As reported by Bloomberg, the French-based Sanofi received 2.07 billion in sales from Plavix® last year.  In 2008, France’s national health system paid 625 million euros on the drug—the most of any pharmaceutical.  Sanofi was recently fined 40.6 million euros ($52.8 million) by France’s largest competition regulator for anti-competitive actions.  Sanofi had been urging doctors to prescribe Plavix® instead of the cheaper generic versions.  Sanofi urged doctors to write prescriptions that the generic version of Plavix® was ineffective and that the generic could not be substituted.  Additionally, Sanofi was urging pharmacists to use Sanofi’s own generic, rather than one from a competitor.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

Plavix®, marketed by Bristol-Myers Squibb and Sanofi Pharmaceuticals, is the second most commonly prescribed drug on the U.S. market to prevent heart attacks and stroke.  The medication, known as a “clopidogrel,” is a blood thinner that belongs to a category of drugs called antiplatelets.  The drug works to prevent blood clots.

 A recent study by the Neurological Disorders and Stroke (NINDS) concludes that Plavix® offers no further benefits than other competing antiplatelet medications and may actually increase the risk of suffering a heart attack or stroke.  Previous studies have discussed the harm of this common combination of Plavix® and aspirin.

As we have previously reported, Plavix® litigation continues to proceed in New Jersey State and Federal courts.   If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

The United States Department of Justice (“DOJ”) is concerned that the dangers of Plavix® were not properly identified by its manufacturers Sanofi-Aventis and Bristol-Myers Squibb.  The DOJ is concerned that the manufacturers failed to disclose certain information in hopes of misleading consumers about the safety of the drug.  Studies show that certain individuals have a difficult time metabolizing Plavix®.  The DOJ was troubled with the warning and “is investigating disclosures to the FDA regarding the variability of response to Plavix” according to Sanofi. This is not the first time Sanofi and Bristol-Myers have been questioned about their Plavix® disclosures.  The FDA inquired into the drug’s safety back in 2003.   A warning was added to the box to flag the differences in Plavix®,effectiveness back in 2010.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.

Plavix, manufactured by Sanofi-Aventis and Bristol-Myers Squibb (collectively, “Defendants”), is a blood thinner prescribed to prevent heart attacks, strokes and blood clotting. However, the users of Plavix have alleged various forms of severe side-effects. Reportedly, these side-effects include: gastrointestinal bleeding, cerebral bleeding, bleeding ulcers, Thrombotic Thrombocytopenic Purpura (TTP), heart attack, stroke and death.

In February 2013, the United States Judicial Panel (“Panel”) on Multi-District Litigation (“MDL”) ruled to consolidate all federal district cases in the District of New Jersey. The MDL 2418, In Re Plavix Marketing, Sales Practices and Products Liability Litigation, will be handled by Judge Freda L.Wolfson, who will manage all pre-trial issues for all federal Plavix cases. This recent ruling overturns the Panel’s 2011, ruling wherein it rejected the motion to consolidate due, in part, to the limited number of cases. However, in reconsidering its prior decision, the Panel concluded that there had been a significant change in circumstances. Recent reports suggest that there is estimated to be more than 2,000 state Plavix cases with an expectation that the federal actions will similarly increase.

The granting of MDL treatment will streamline the lawsuits, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.  Additionally, MDL treatment will provide more convenience for the witnesses, the parties and the court.  It is also anticipated that Judge Woflson will coordinate the federal cases with the New Jersey state Plavix cases, which are currently centralized before Jessica Mayer in Middlesex County.

If you feel you have experienced any side-effects from taking Plavix®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Plavix® manufacturers.